Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX

NCT01493713 is registered in ClinicalTrials.gov with Grupo Espanol Multidisciplinario del Cancer Digestivo as lead sponsor.

NCT NCT01493713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01493713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX
Lead sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase
Phase 4
Overall status
Completed
Start date
November 16, 2011
Completion date
December 18, 2017
Enrollment
83 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, hepatic metastasis